Company intelligence / Profile preview

Propel

Pittsboro, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Propella Therapeutics is a clinical-stage biotechnology company focused on developing highly selective, next-generation oncology therapeutics. The company utilizes a proprietary medicinal chemistry platform to design drugs with improved safety and efficacy profiles, specifically targeting validated pathways in cancer. Its lead program, CTP-439, is a novel prodrug of abiraterone designed to provide superior pharmacokinetic properties for the treatment of metastatic castration-resistant prostate cancer. In late 2023, Propella was acquired by Roche to bolster its oncology pipeline and leverage Propella's expertise in selective small molecule design.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Roche

Beyond the preview

Go deeper on Propel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Propel.

Explore the full profile